Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR4 | O95977 | 2/20 | 0.58 |
| ▸ | MAPT | P10636 | 2/20 | 0.58 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.58 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.58 |
| ▸ | JAK2 | O60674 | 1/20 | 0.58 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.58 |
| ▸ | HTT | P42858 | 1/20 | 0.58 |
| ▸ | TXNRD1 | Q16881 | 18/20 | 0.57 |
| ▸ | GSR | P00390 | 2/20 | 0.57 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | GFER | P55789 | 1/20 | 0.52 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29391771 | 1.00 | S1PR4 (0.58) | S1PR4MAPTS1PR1MAPK1NPSR1 | |
| SCHEMBL1428159 | 0.84 | TXNRD1 (0.58) | S1PR4MAPTS1PR1MAPK1NPSR1 | |
| SCHEMBL19100650 | 0.83 | TXNRD1 (0.47) | S1PR4MAPTS1PR1MAPK1NPSR1 | |
| SCHEMBL19156270 | 0.82 | S1PR4 (0.44) | S1PR4MAPTS1PR1MAPK1NPSR1 | |
| SCHEMBL7836089 | 0.82 | TXNRD1 (0.56) | S1PR4MAPTS1PR1MAPK1NPSR1 | |
| SCHEMBL7836091 | 0.82 | TXNRD1 (0.56) | S1PR4MAPTS1PR1MAPK1NPSR1 | |
| SCHEMBL7836090 | 0.82 | TXNRD1 (0.56) | S1PR4MAPTS1PR1MAPK1NPSR1 | |
| SCHEMBL30271362 | 0.81 | MAOA (0.48) | S1PR4MAPTS1PR1MAPK1NPSR1 | |
| SCHEMBL10654156 | 0.81 | MAOA (0.48) | S1PR4MAPTS1PR1MAPK1NPSR1 | |
| SCHEMBL27226468 | 0.80 | MAPT (0.41) | S1PR4MAPTS1PR1MAPK1NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 688 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113480541-B | Process for producing imidazopyridine compound and intermediate thereof | 湖南化工研究院有限公司 | 2022-09-02 | — | — | CN | claimed |
| CN-113480541-A | Process for producing imidazopyridine compound and intermediate thereof | 湖南化工研究院有限公司 | 2021-10-08 | — | — | CN | claimed |
| CN-111662283-A | Imidazopyridine compound and intermediate, preparation method and application thereof | 湖南化工研究院有限公司 | 2020-09-15 | — | — | CN | claimed |
| WO-2001038306-A9 | NOVEL 3-NITROPYRIDINE DERIVATIVES AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING SAID DERIVATIVES | DONG WHA PHARM IND CO LTD (KR) | 2003-06-19 | — | — | WO | claimed |
| EP-1235804-A1 | NOVEL 3-NITROPYRIDINE DERIVATIVES AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING SAID DERIVATIVES | DONG WHA PHARMACEUTICAL INDUSTRIAL CO. LTD. (KR) | 2002-09-04 | — | — | EP | claimed |
| WO-2001038306-A1 | NOVEL 3-NITROPYRIDINE DERIVATIVES AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING SAID DERIVATIVES | DONG WHA PHARM. IND. CO., LTD (KR) | 2001-05-31 | — | — | WO | claimed |
| US-6176909-B1 | IN POLYMERIC BINDER | XEROX CORPORATION | 2001-01-23 | — | — | US | claimed |
| US-20260097034-A1 | METALLOENZYME INHIBITOR COMPOUNDS | CORXEL PHARMACEUTICALS HONG KONG LTD (HK) | 2026-04-09 | — | — | US | disclosed |
| US-12509431-B2 | 1,4-dihydroquinazolinone compounds and uses thereof | EDGEWISE THERAPEUTICS, INC. (US) | 2025-12-30 | — | — | US | disclosed |
| US-20250368647-A1 | NITROGEN CONTAINING CONDENSED 2,3-DIHYDROQUINAZOLINONE COMPOUNDS AS NAV1.8 INHIBITORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2025-12-04 | — | — | US | disclosed |
| US-20250361213-A1 | 1,4-DIHYDROQUINAZOLINONE COMPOUNDS AND USES THEREOF | EDGEWISE THERAPEUTICS INC (US) | 2025-11-27 | — | — | US | disclosed |
| US-20250353842-A1 | BICYCLIC AMINE CDK12 INHIBITORS | INCYTE CORP (US) | 2025-11-20 | — | — | US | disclosed |
| US-12458642-B2 | Metalloenzyme inhibitor compounds | CORXEL PHARMACEUTICALS HONG KONG LIMITED (HK) | 2025-11-04 | — | — | US | disclosed |
| US-4567272-A | Pyrrole containing 2-aminonitropyridine derivatives | RUTGERSWERKE AKTIENGESELLSCHAFT (DE) | 1986-01-28 | — | — | US | disclosed |
| EP-0102652-B1 | METHOD FOR THE PREPARATION OF PURE 2-CHLORO-6-ALKOXY-3-NITRO-PYRIDINES | RÜTGERSWERKE AKTIENGESELLSCHAFT (DE) | 1986-01-08 | — | — | EP | disclosed |
| US-4558132-A | ANTIDEPRESSANTS | A. H. ROBINS COMPANY, INCORPORATED (US) | 1985-12-10 | — | — | US | disclosed |
| US-4529800-A | Novel process for the preparation of 2-halo-3-nitro-6-alkoxy-pyridines | RUTGERSWERKE AKTIENGESELLSCHAFT (DE) | 1985-07-16 | — | — | US | disclosed |
| EP-0136730-A1 | 2-Aminonitropyridine derivatives and process for the preparation thereof | RÜTGERSWERKE AKTIENGESELLSCHAFT (DE) | 1985-04-10 | — | — | EP | disclosed |
| EP-0102652-A1 | Method for the preparation of pure 2-chloro-6-alkoxy-3-nitro-pyridines | RÜTGERSWERKE AKTIENGESELLSCHAFT (DE) | 1984-03-14 | — | — | EP | disclosed |
| EP-0099614-A2 | Nitro, amino and aroylamino-N-phenylpyridinamines and their use in a process for preparing pyrido(1,4)benzodiazapines | A.H. ROBINS COMPANY, INCORPORATED (US) | 1984-02-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12458642-B2 | Metalloenzyme inhibitor compounds | CYP11B2, CYP11B1, HSD11B2 | S1PR4 4597/4885MAPT 2593/4885S1PR1 3713/4885 |
| US-20250368647-A1 | NITROGEN CONTAINING CONDENSED 2,3-DIHYDROQUINAZOLINONE COMPOUNDS AS NAV1.8 INHIBITORS | SCN8A, SCN2A, SCN5A | S1PR4 4453/4885MAPT 2351/4885S1PR1 4468/4885 |
| US-20250353842-A1 | BICYCLIC AMINE CDK12 INHIBITORS | CDK12, CDK1, CDK2 | S1PR4 3079/4885MAPT 1626/4885S1PR1 2425/4885 |
| US-12509431-B2 | 1,4-dihydroquinazolinone compounds and uses thereof | TNNT2, TNNI3, TNNC1 | S1PR4 1700/4885MAPT 4455/4885S1PR1 1373/4885 |
| US-20260097034-A1 | METALLOENZYME INHIBITOR COMPOUNDS | CPN1, TPP1, DPP4 | S1PR4 4153/4885MAPT 2173/4885S1PR1 3813/4885 |
| US-20250361213-A1 | 1,4-DIHYDROQUINAZOLINONE COMPOUNDS AND USES THEREOF | TNNI3, TNNT2, SDHA | S1PR4 2370/4885MAPT 3072/4885S1PR1 3333/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.